<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37133944</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1660-9379</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>824</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>Revue medicale suisse</Title><ISOAbbreviation>Rev Med Suisse</ISOAbbreviation></Journal><ArticleTitle>[Similarities between amyotrophic lateral sclerosis and frontotemporal dementia].</ArticleTitle><Pagination><StartPage>820</StartPage><EndPage>821</EndPage><MedlinePgn>820-821</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.53738/REVMED.2023.19.824.820</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) is characterized by degeneration of the frontal and temporal lobes. Classic symptoms include behavioural alterations and executive dysfunction. Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease of the first and second motoneurones, as well as of cortical neurons, presenting with weakness and wasting of the limb, respiratory and bulbar muscles. Accumulation of a mis-localized protein in the neuronal cytoplasma is the main neuropathological marker of ALS but has also been described in certain FTD-variants. Molecules interfering specifically on this level of mis-localization and toxic aggregation may thus represent a very interesting therapeutic approach in both, ALS and FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xfc;bers</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3088-0366</Identifier><AffiliationInfo><Affiliation>Unit&#xe9; des maladies neuromusculaires, Service de neurologie, D&#xe9;partement des neurosciences cliniques, H&#xf4;pitaux universitaires de Gen&#xe8;ve, 1211 Gen&#xe8;ve 14.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Similarit&#xe9;s entre scl&#xe9;rose lat&#xe9;rale amyotrophique et d&#xe9;mence frontotemporale.</VernacularTitle></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Rev Med Suisse</MedlineTA><NlmUniqueID>101219148</NlmUniqueID><ISSNLinking>1660-9379</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>La d&#xe9;mence frontotemporale (DFT) appartient au spectre des d&#xe9;g&#xe9;n&#xe9;rescences frontotemporales et se pr&#xe9;sente classiquement par une atteinte comportementale et ex&#xe9;cutive. La scl&#xe9;rose lat&#xe9;rale amyotrophique (SLA) affecte les motoneurones ainsi que des neurones corticaux, se manifestant classiquement par une amyotrophie, une faiblesse ou des troubles de l&#x2019;&#xe9;locution. Le temps de survie n&#x2019;est que de trois &#xe0; cinq ans en moyenne. Le marqueur neuropathologique majeur de la SLA est une accumulation toxique de certaines prot&#xe9;ines dans les neurones. Ces m&#xea;mes agr&#xe9;gations sont &#xe9;galement pr&#xe9;sentes dans certaines formes de la DFT, parlant en faveur des pathom&#xe9;canismes communs. De ce fait, des mol&#xe9;cules intervenant sp&#xe9;cifiquement au niveau de ces processus repr&#xe9;sentent une approche th&#xe9;rapeutique tr&#xe8;s prometteuse pour les patients atteints d&#x2019;une SLA ou d&#x2019;une DFT.</AbstractText></OtherAbstract><CoiStatement>L&#x2019;auteure n&#x2019;a d&#xe9;clar&#xe9; aucun conflit d&#x2019;int&#xe9;r&#xea;ts en relation avec cet article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37133944</ArticleId><ArticleId IdType="doi">10.53738/REVMED.2023.19.824.820</ArticleId><ArticleId IdType="pii">RMS0824-011</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>